Bal Pharma Ltd (BALPHARMA) — shareholding pattern, promoter holding, financials and share price
About Bal Pharma Ltd (BALPHARMA)
Bal Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BALPHARMA and on the BSE under scrip code 524824. Its ISIN is INE083D01012.
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services [1]
Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc.
The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing.
Listed peers in Pharmaceuticals: Smruthi Organics Ltd, Lactose (India) Ltd, Tyche Industries Ltd, Godavari Drugs Ltd, Pharmaids Pharmaceuticals Ltd, Krebs Biochemicals & Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹79.68 a share on 10 Jul 2026, Bal Pharma Ltd (BALPHARMA) was valued at a price-to-earnings ratio of 20.07x against an industry P/E of 36.41x and a price-to-book of 1.64x on a book value of ₹48.63 per share as of Mar 2025. Solomo computes return on equity of 8.16% and return on capital employed of 9.99% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 20.07x
- Industry P/E
- 36.41x
- P/B
- 1.64x
- EPS (TTM)
- ₹3.97
- Book value / share
- ₹48.63
- ROE
- 8.16%
- ROCE
- 9.99%
- ROA
- 1.88%
- Debt / equity
- 1.94x
- Dividend yield
- 1.88%
- EBITDA margin
- 10.85%
- 52-week range
- ₹59.69 – ₹112.97
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Bal Pharma Ltd (BALPHARMA) reported revenue of ₹312 crore, net profit of ₹6 crore and earnings per share of ₹3.94. That compares with revenue of ₹303 crore and net profit of ₹7 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹84.08 crore and net profit ₹3.6 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 281 | 304 | 339 | 303 | 312 |
| Net profit (₹ cr) | 6 | 3 | 7 | 7 | 6 |
| EPS (₹) | 3.78 | 1.64 | 4.68 | 4.53 | 3.94 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.60% | 12.13% | 2.56% | -10.65% |
| Profit growth | 12.03% | - | -3.12% | -2.82% |
| Stock price CAGR | -1% | -3% | -3% | -13% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.86% of Bal Pharma Ltd (BALPHARMA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.15%. Market capitalisation was ₹127 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Prakash Chandra Jain 3.44%, Ram Keshav Murthy 3.31%, HUF 2.7%, Naresh D P 1.88%, Shreya Mardia 1.88%, Asha Tapidas Dodhia 1.84%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.86% | - | 0.15% | - | 49.14% |
| Mar 2026 | 50.86% | - | 0.14% | - | 49.14% |
| Dec 2025 | 50.86% | - | 0.14% | - | 49.14% |
| Sep 2025 | 50.86% | - | 0.22% | - | 49.14% |
| Jun 2025 | 50.86% | - | 0.15% | - | 49.14% |
| Mar 2025 | 50.86% | - | 0.14% | - | 49.14% |
| Dec 2024 | 50.86% | - | 0.14% | - | 49.14% |
| Sep 2024 | 50.86% | - | 0.13% | - | 49.14% |